PIK3CG and urinary bladder cancer: NVP-BEZ235 (Dactolisib) is an oral mTOR/PI3K dual inhibitor [186] and has been shown to suppress tumor cell growth by inducing cell cycle arrest and caspase-dependent apoptosis in eight different human bladder cancer cell lines [167].